Search

Search Constraints

You searched for: Author/Creator Huizinga, Thomas

Search Results

1. 078 Reductions in absolute neutrophil count with sarilumab resulting in dose delays or dose decreases: effects on efficacy and safety. (12th April 2019)

2. 080 Long-term treatment with sarilumab plus conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs): pooled safety and efficacy with over 4 years' treatment. (12th April 2019)

3. AB0222 ASSOCIATION BETWEEN CENTROMERE AND TOPOISOMERASE SPECIFIC IMMUNE RESPONSES AND THE DEGREE OF MICROANGIOPATHY IN SYSTEMIC SCLEROSIS. (June 2019)

4. AB1282 A BIG-DATA APPROACH TO ELECTRONIC HEALTH RECORD DATA – USING DIMENSIONALITY REDUCTION AND CLUSTERING TECHNIQUES TO STUDY LONGITUDINAL RELATIONSHIPS BETWEEN DISEASES. (June 2019)

6. FRI0081 WITHDRAWAL OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE SARILUMAB OPEN-LABEL EXTEND STUDY: EFFICACY AND SAFETY ANALYSIS. (June 2019)

7. FRI0123 BIOLOGICAL THERAPIES SURVIVAL IN RHEUMATOID ARTHRITIS PATIENTSIN CLINICAL PRACTICE: RESULTS FROM THE METEOR REGISTRY. (June 2019)

9. OP0042 LONG-TERM EFFECTS OF SYNERGETIC B CELL IMMUNOMODULATION WITH RITUXIMAB AND BELIMUMAB COMBINATION TREATMENT IN SEVERE, REFRACTORY SLE: TWO YEAR RESULTS. (June 2019)

10. OP0295 N-LINKED GLYCANS IN THE VARIABLE DOMAIN OF ACPA-IGG IN THE DEVELOPMENT OF RHEUMATOID ARTHRITIS. (June 2019)